JP6635527B2 - 高尿酸血症又は痛風の治療又は予防用化合物 - Google Patents
高尿酸血症又は痛風の治療又は予防用化合物 Download PDFInfo
- Publication number
- JP6635527B2 JP6635527B2 JP2018512946A JP2018512946A JP6635527B2 JP 6635527 B2 JP6635527 B2 JP 6635527B2 JP 2018512946 A JP2018512946 A JP 2018512946A JP 2018512946 A JP2018512946 A JP 2018512946A JP 6635527 B2 JP6635527 B2 JP 6635527B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- ketone
- pyridin
- ethylimidazo
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510576110 | 2015-09-10 | ||
| CN201510576110.7 | 2015-09-10 | ||
| PCT/CN2016/098468 WO2017041732A1 (zh) | 2015-09-10 | 2016-09-08 | 一类用于治疗或预防高尿酸血症或痛风的化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526417A JP2018526417A (ja) | 2018-09-13 |
| JP6635527B2 true JP6635527B2 (ja) | 2020-01-29 |
Family
ID=58164535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512946A Active JP6635527B2 (ja) | 2015-09-10 | 2016-09-08 | 高尿酸血症又は痛風の治療又は予防用化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10399971B2 (https=) |
| EP (1) | EP3348557B1 (https=) |
| JP (1) | JP6635527B2 (https=) |
| KR (1) | KR102109061B1 (https=) |
| CN (1) | CN106432229B (https=) |
| AU (1) | AU2016320073B2 (https=) |
| BR (1) | BR112018004863B1 (https=) |
| CA (1) | CA2998034C (https=) |
| CY (1) | CY1123137T1 (https=) |
| DK (1) | DK3348557T3 (https=) |
| EA (1) | EA037280B1 (https=) |
| ES (1) | ES2803223T3 (https=) |
| HR (1) | HRP20201094T1 (https=) |
| HU (1) | HUE051448T2 (https=) |
| IL (1) | IL257960A (https=) |
| LT (1) | LT3348557T (https=) |
| MX (1) | MX375068B (https=) |
| MY (1) | MY195675A (https=) |
| NZ (1) | NZ741318A (https=) |
| PL (1) | PL3348557T3 (https=) |
| PT (1) | PT3348557T (https=) |
| RS (1) | RS60697B1 (https=) |
| SG (1) | SG11201802010QA (https=) |
| SI (1) | SI3348557T1 (https=) |
| TW (1) | TWI681772B (https=) |
| WO (1) | WO2017041732A1 (https=) |
| ZA (1) | ZA201802312B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018090921A1 (zh) * | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN108084186B (zh) * | 2016-11-16 | 2021-06-25 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| EP3632904B1 (en) * | 2017-05-26 | 2022-04-20 | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. | Urat1 inhibitors for promoting uric acid excretion |
| CN114213331B (zh) * | 2017-05-26 | 2024-06-21 | 江苏新元素医药科技有限公司 | 一类urat1抑制剂及其应用 |
| CN112979661B (zh) * | 2018-01-19 | 2022-05-17 | 苏州信诺维医药科技股份有限公司 | 杂环化合物、制备方法及其在医药上的应用 |
| CN111410654B (zh) * | 2019-01-19 | 2022-05-17 | 江苏新元素医药科技有限公司 | 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| WO2022169974A1 (en) | 2021-02-05 | 2022-08-11 | Nexys Therapeutics, Inc. | Inhibitors of urat1 and pharmaceutical uses thereof |
| CN113717072A (zh) * | 2021-09-28 | 2021-11-30 | 铜仁百朗制药有限公司 | 一种治疗便秘药物中间体的制备方法 |
| CN116715633B (zh) * | 2022-04-27 | 2025-08-12 | 杭州新元素药业股份有限公司 | 可用于降尿酸的化合物 |
| WO2023221078A1 (en) * | 2022-05-20 | 2023-11-23 | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. | Solid forms of a compound for treating or preventing hyperuricemia or gout |
| TWI898321B (zh) * | 2023-11-17 | 2025-09-21 | 大陸商杭州新元素藥業有限公司 | 用於治療或預防高尿酸血症或痛風的化合物的固體晶型 |
| WO2025237171A1 (zh) * | 2024-05-11 | 2025-11-20 | 广州市联瑞制药有限公司 | 嘧啶并五元氮杂环酚类化合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ193926A (en) * | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
| FR2647451B1 (fr) | 1989-05-26 | 1994-08-05 | Sanofi Sa | Derives d'imidazo(1,2-a)pyridine, procede de preparation, compositions pharmaceutiques les contenant |
| JP5325065B2 (ja) * | 2009-09-30 | 2013-10-23 | 株式会社富士薬品 | 新規フェノール誘導体 |
| US10005750B2 (en) * | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
| WO2014017643A1 (ja) * | 2012-07-27 | 2014-01-30 | 佐藤製薬株式会社 | ジフルオロメチレン化合物 |
-
2016
- 2016-09-08 KR KR1020187010142A patent/KR102109061B1/ko active Active
- 2016-09-08 CN CN201610810990.4A patent/CN106432229B/zh active Active
- 2016-09-08 SG SG11201802010QA patent/SG11201802010QA/en unknown
- 2016-09-08 ES ES16843670T patent/ES2803223T3/es active Active
- 2016-09-08 HR HRP20201094TT patent/HRP20201094T1/hr unknown
- 2016-09-08 HU HUE16843670A patent/HUE051448T2/hu unknown
- 2016-09-08 MY MYPI2018700948A patent/MY195675A/en unknown
- 2016-09-08 JP JP2018512946A patent/JP6635527B2/ja active Active
- 2016-09-08 EP EP16843670.7A patent/EP3348557B1/en active Active
- 2016-09-08 NZ NZ741318A patent/NZ741318A/en unknown
- 2016-09-08 DK DK16843670.7T patent/DK3348557T3/da active
- 2016-09-08 US US15/758,866 patent/US10399971B2/en active Active
- 2016-09-08 SI SI201630859T patent/SI3348557T1/sl unknown
- 2016-09-08 PL PL16843670T patent/PL3348557T3/pl unknown
- 2016-09-08 RS RS20200901A patent/RS60697B1/sr unknown
- 2016-09-08 WO PCT/CN2016/098468 patent/WO2017041732A1/zh not_active Ceased
- 2016-09-08 CA CA2998034A patent/CA2998034C/en active Active
- 2016-09-08 PT PT168436707T patent/PT3348557T/pt unknown
- 2016-09-08 BR BR112018004863-1A patent/BR112018004863B1/pt active IP Right Grant
- 2016-09-08 MX MX2018003006A patent/MX375068B/es active IP Right Grant
- 2016-09-08 AU AU2016320073A patent/AU2016320073B2/en active Active
- 2016-09-08 LT LTEP16843670.7T patent/LT3348557T/lt unknown
- 2016-09-08 EA EA201890694A patent/EA037280B1/ru unknown
- 2016-09-30 TW TW105131659A patent/TWI681772B/zh active
-
2018
- 2018-03-07 IL IL257960A patent/IL257960A/en active IP Right Grant
- 2018-04-09 ZA ZA2018/02312A patent/ZA201802312B/en unknown
-
2020
- 2020-07-17 CY CY20201100660T patent/CY1123137T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6635527B2 (ja) | 高尿酸血症又は痛風の治療又は予防用化合物 | |
| TWI471325B (zh) | Indole (Indolizine) derivatives and their pharmaceutical use | |
| JP6925054B2 (ja) | Ｕｒａｔ１抑制剤及びその使用 | |
| CN110167918A (zh) | 新型苯基衍生物 | |
| KR102420892B1 (ko) | 요산 배출을 촉진시키는 urat1 억제제 | |
| CN107683282B (zh) | Urat1抑制剂及其在医药上的应用 | |
| JP2003531856A (ja) | リン酸輸送阻害剤 | |
| CN114213331B (zh) | 一类urat1抑制剂及其应用 | |
| JP2016500115A (ja) | ２−アリールセレナゾール化合物及びその薬剤組成物 | |
| CN107759588B (zh) | 一类苯基-(吡唑并[1,5-a]吡啶-3-基)甲酮衍生物 | |
| CN107635981A (zh) | 用于诱导白色脂肪组织褐变的化合物和方法 | |
| WO1999007382A1 (en) | Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases | |
| WO2021000527A1 (zh) | 三环类xor抑制剂及其制备方法和应用 | |
| CN111793066B (zh) | 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180322 |
|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20180508 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180508 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180322 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190820 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191029 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191119 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191212 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6635527 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |